18F-Labeled Normemantine for NMDA Receptor PET Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current NMDA receptor antagonists for medical imaging have limitations such as non-specificity, short half-life of radiolabels, and undesirable side effects, which hinder effective detection and therapeutic use in neurological diseases.
Innovation Solution
Development of a novel 18F-labeled memantine derivative, 2-fluoroethyl normemantine, with improved affinity for NMDA receptors and brain distribution, allowing for effective labeling and visualization via PET scans, and potentially reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional NMDA receptor antagonists are used for medical imaging, then receptor binding is achieved, but side effects increase and specificity decreases
Solution Approach 1:
The patent modifies the chemical structure of memantine by introducing fluorine atoms at specific positions (2-fluoroethyl normemantine) to change the molecular parameters. This structural modification maintains NMDA receptor binding affinity while reducing side effects such as headaches, dizziness, and hallucinations associated with conventional antagonists.
Solution Approach 2:
The invention introduces fluorine substitution at specific local positions on the memantine molecule (position 2 on the ethyl chain) to achieve localized improvement in selectivity and reduced side effects, while maintaining the overall pharmacophore structure necessary for NMDA receptor binding.
2Speed
If radiolabels with short half-life are used, then detection speed increases, but detection effectiveness decreases due to insufficient time for production-injection-detection protocol
Solution Approach 1:
The patent utilizes fluorine-18 labeling, which has a half-life of approximately 110 minutes, providing an optimal balance between detection speed and effectiveness. This allows sufficient time for radiopharmaceutical production, quality control, injection, and PET imaging while maintaining high detection effectiveness through the positron emission properties of fluorine-18.
3Reliability
If 18F-memantine is used for NMDA receptor labeling, then receptor affinity is maintained, but brain concentration is insufficient for effective imaging
Solution Approach 1:
The patent introduces fluorine substitution at the 2-position of the ethyl chain in normemantine, creating a localized modification that improves lipophilicity and brain penetration. This local structural change increases brain concentration to 3.6% ID/g at 60 minutes post-injection, while preserving the essential pharmacophore for NMDA receptor binding.
Solution Approach 2:
The fluorine substitution modifies key molecular parameters including lipophilicity (logP), molecular volume, and electronic distribution, thereby enhancing blood-brain barrier penetration and brain tissue distribution while maintaining NMDA receptor affinity through preservation of the core adamantane amino structure.
4Reliability
If NMDA receptor antagonists are developed for therapeutic use, then neurological disease treatment is improved, but side effects preclude general recommendation
Solution Approach 1:
The patent describes 2-fluoroethyl normemantine derivatives that modify the pharmacological parameters of conventional memantine, achieving enhanced therapeutic efficacy for neurological diseases while significantly reducing side effects. Clinical evaluation shows reduced incidence of headaches, dizziness, and hallucinations compared to unmodified memantine.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The 18F-labeled derivative enables better imaging of NMDA receptors with enhanced brain penetration and reduced toxicity, facilitating the study of neurological diseases and drug treatment effects while minimizing side effects.
Implementation Method 1
the 18F-labeled derivative enables better imaging of NMDA receptors with enhanced brain penetration
Implementation Method 2
allowing for effective labeling and visualization via PET scans
Data Source
AI summary
The present invention concerns novel chemical compounds corresponding to formulae (I) and (II): (I) (II) which, when marked with fluorine-18, can be used as markers of NMDA receptors for carrying out studies with a scanner.